Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Femasys (NASDAQ:FEMY) posted its earnings results on Friday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02, Zacks reports. The company had revenue of $0.73 million for the quarter. Femasys had a negative return on equity of 713.74% and a negative net margin of 1,113.72%.

Femasys Price Performance

Shares of FEMY stock traded up $0.07 on Friday, reaching $0.90. 3,534,457 shares of the company’s stock were exchanged, compared to its average volume of 11,556,732. The company’s fifty day simple moving average is $0.57 and its 200 day simple moving average is $0.77. Femasys has a 52 week low of $0.31 and a 52 week high of $1.80. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.89 and a quick ratio of 0.41.

Analysts Set New Price Targets

FEMY has been the topic of several recent research reports. HC Wainwright decreased their price objective on Femasys from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Wall Street Zen raised shares of Femasys to a “sell” rating in a research note on Saturday, October 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Institutional Trading of Femasys

A hedge fund recently bought a new stake in Femasys stock. Osaic Holdings Inc. purchased a new position in Femasys Inc. (NASDAQ:FEMY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,055 shares of the company’s stock, valued at approximately $45,000. Osaic Holdings Inc. owned about 0.14% of Femasys at the end of the most recent quarter. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.